PL1771468T3 - Zasiedlające nowotwory komórki inżynierowane w celu wytwarzania ligandu czynnika martwicy nowotworu indukującego apoptozę (TRAIL) - Google Patents

Zasiedlające nowotwory komórki inżynierowane w celu wytwarzania ligandu czynnika martwicy nowotworu indukującego apoptozę (TRAIL)

Info

Publication number
PL1771468T3
PL1771468T3 PL05764208T PL05764208T PL1771468T3 PL 1771468 T3 PL1771468 T3 PL 1771468T3 PL 05764208 T PL05764208 T PL 05764208T PL 05764208 T PL05764208 T PL 05764208T PL 1771468 T3 PL1771468 T3 PL 1771468T3
Authority
PL
Poland
Prior art keywords
tumor
necrosis factor
ligand
trail
apoptosis
Prior art date
Application number
PL05764208T
Other languages
English (en)
Polish (pl)
Inventor
Alessandro M Gianni
Carmelo Carlo-Stella
Francesco Colotta
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Publication of PL1771468T3 publication Critical patent/PL1771468T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL05764208T 2004-07-29 2005-07-21 Zasiedlające nowotwory komórki inżynierowane w celu wytwarzania ligandu czynnika martwicy nowotworu indukującego apoptozę (TRAIL) PL1771468T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04017907A EP1621550A1 (en) 2004-07-29 2004-07-29 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
EP05764208A EP1771468B1 (en) 2004-07-29 2005-07-21 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail)
PCT/EP2005/007957 WO2006010558A1 (en) 2004-07-29 2005-07-21 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail)

Publications (1)

Publication Number Publication Date
PL1771468T3 true PL1771468T3 (pl) 2010-07-30

Family

ID=34925971

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05764208T PL1771468T3 (pl) 2004-07-29 2005-07-21 Zasiedlające nowotwory komórki inżynierowane w celu wytwarzania ligandu czynnika martwicy nowotworu indukującego apoptozę (TRAIL)

Country Status (24)

Country Link
US (1) US20070264231A1 (OSRAM)
EP (2) EP1621550A1 (OSRAM)
JP (1) JP5042826B2 (OSRAM)
KR (1) KR20070047757A (OSRAM)
CN (1) CN101076540B (OSRAM)
AT (1) ATE455847T1 (OSRAM)
AU (1) AU2005266543B2 (OSRAM)
BR (1) BRPI0513855A (OSRAM)
CA (1) CA2571426A1 (OSRAM)
DE (1) DE602005019050D1 (OSRAM)
DK (1) DK1771468T3 (OSRAM)
ES (1) ES2340400T3 (OSRAM)
HR (1) HRP20100227T1 (OSRAM)
IL (1) IL180233A (OSRAM)
MX (1) MX2007001152A (OSRAM)
NO (1) NO20070956L (OSRAM)
NZ (1) NZ552223A (OSRAM)
PL (1) PL1771468T3 (OSRAM)
PT (1) PT1771468E (OSRAM)
RS (1) RS51381B (OSRAM)
RU (1) RU2390558C2 (OSRAM)
SI (1) SI1771468T1 (OSRAM)
WO (1) WO2006010558A1 (OSRAM)
ZA (1) ZA200701231B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008503468A (ja) * 2004-06-18 2008-02-07 ジェネンテック・インコーポレーテッド Ａｐｏ２ｌレセプターアゴニストおよびｎｋ細胞活性化因子の使用方法
DE102006020307A1 (de) * 2006-05-03 2007-11-08 Martin-Luther-Universität Halle-Wittenberg TNF-related apoptosis-including (TRAIL)stabil transgen exprimierende mesenchymale Stammzellen, Verfahren zu ihrer Herstellung und zu ihrer Verwendung
WO2008142862A1 (ja) * 2007-05-18 2008-11-27 National University Corporation Asahikawa Medical College 血管内皮前駆細胞の移植による抗がん療法
CN102154213B (zh) * 2011-01-19 2012-07-25 郑骏年 一种运载荷载细胞因子的双调控溶瘤腺病毒的新型cik细胞
CN104160027B (zh) * 2012-02-01 2016-06-22 浦项工科大学校产学协力团 同时表达十二聚体trail及hsv-tk自杀基因的载体及利用其的抗癌干细胞治疗剂
CN103288966B (zh) * 2013-05-17 2015-01-21 华侨大学 一种融合受体及其用于治疗大肠癌的基因药物
RU2552609C1 (ru) * 2013-10-28 2015-06-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов
WO2016065330A1 (en) 2014-10-24 2016-04-28 Aladar Szalay Combination immunotherapy approach for treatment of cancer
CN116064401A (zh) * 2015-07-29 2023-05-05 昂克医疗有限公司 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
WO2019232631A1 (en) * 2018-06-06 2019-12-12 Stemcell Technologies Canada Inc. Kits, compositions and methods for myeloid-derived suppressor cell enrichment
US12220465B2 (en) 2018-11-28 2025-02-11 Washington University Compositions and methods for targeted treatment and imaging of cancer or tumors
EP3712257A1 (en) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modified natural killer cells with increased resistance to cell death
CN113677791B (zh) * 2019-03-21 2024-12-03 昂克医疗有限公司 对细胞死亡具有增加的抗性的经修饰的免疫效应细胞
WO2021209625A1 (en) 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
AU747602B2 (en) * 1997-06-04 2002-05-16 Oxford Biomedica (Uk) Limited Vector
WO2002022175A2 (en) * 2000-09-11 2002-03-21 Musc Foundation For Research Development Method and composition for treating tumors by selective induction of apoptosis
EP1427813A2 (en) * 2000-10-24 2004-06-16 Immunex Corporation Method for dendritic cells-based immunotherapy of tumors using combination therapy
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP4493882B2 (ja) * 2001-06-19 2010-06-30 株式会社カネカ 抗原およびこの抗原を識別するモノクローナル抗体

Also Published As

Publication number Publication date
AU2005266543B2 (en) 2012-02-02
EP1771468B1 (en) 2010-01-20
EP1621550A1 (en) 2006-02-01
ZA200701231B (en) 2008-08-27
NZ552223A (en) 2009-01-31
RS51381B (sr) 2011-02-28
EP1771468A1 (en) 2007-04-11
PT1771468E (pt) 2010-04-20
ATE455847T1 (de) 2010-02-15
CA2571426A1 (en) 2006-02-02
HK1110874A1 (en) 2008-07-25
WO2006010558A1 (en) 2006-02-02
RU2007107369A (ru) 2008-09-10
WO2006010558A8 (en) 2006-08-24
JP2008507961A (ja) 2008-03-21
DK1771468T3 (da) 2010-05-25
KR20070047757A (ko) 2007-05-07
CN101076540B (zh) 2012-10-24
IL180233A0 (en) 2007-07-04
US20070264231A1 (en) 2007-11-15
CN101076540A (zh) 2007-11-21
HRP20100227T1 (hr) 2010-07-31
RU2390558C2 (ru) 2010-05-27
MX2007001152A (es) 2007-04-18
NO20070956L (no) 2007-02-20
AU2005266543A1 (en) 2006-02-02
DE602005019050D1 (de) 2010-03-11
BRPI0513855A (pt) 2008-05-20
SI1771468T1 (sl) 2010-07-30
JP5042826B2 (ja) 2012-10-03
ES2340400T3 (es) 2010-06-02
IL180233A (en) 2010-12-30

Similar Documents

Publication Publication Date Title
DK1771468T3 (da) Tumormålsøgende celler konstrueret til at producere tumornecrosefaktor-beslægtet apoptoseinducerende ligand (TRAIL)
UY28926A1 (es) Adenovirus quiméricos para uso en el tratamiento del cáncer
MX2023007644A (es) Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2.
Danielpour et al. Cross-talk between IGF-I and TGF-β signaling pathways
ZA202110393B (en) Chimeric polypeptide assembly and methods of making and using the same
SA521421744B1 (ar) علاج مناعي توليفي للسرطان
AU2019415848A8 (en) Claudin18.2 binding moieties and uses thereof
CY1116970T1 (el) Fkbp-l και χρησεις αυτων ως αναστολεις αγγειογενεσης
CY1119290T1 (el) Μονοκλωνα αντισωματα κατα κλαουδινης-18 για τη θεραπεια του καρκινου
EA201791971A1 (ru) Онколитический аденовирус, кодирующий белок b7
PH12016502267A1 (en) Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
PH12017502129A1 (en) Antibodies against ox40 and uses thereof
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201891121A1 (ru) Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
ECSP088299A (es) Modulacion de la expresion del receptor de glucagon
WO2018118494A3 (en) Use of car-modified human natural killer cells to treat cancer
DE602006018709D1 (de) Estergebundene geminitensidverbindungen zur verwendung in der gentherapie
WO2018169901A8 (en) Synthetic promoters
SA521422250B1 (ar) أجسام مضادة للبيريوستين واستخداماتها
DE602005007220D1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
MX2010006425A (es) Moduladores de proteina cinasa de objetivos multiples 1,3-ciclopentadiona-substituida de cancer, angiogenesis y las trayectorias inflamatorias asociadas con los mismos.
ATE478076T1 (de) Azaxanthonen zur behandlung von tumoren
DK2066790T3 (da) Galactosyltransferase
ATE512159T1 (de) Cyclodipeptidsynthetasen und ihre verwendung zur synthese von cyclo(leu-leu)cyclodipeptid